Barinthus Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-73.35	5.34	-50.87	-17.71	-20.73
Depreciation & Amortization	6.76	5.54	0.94	0.21	0.35
Share-Based Compensation	5.06	9.88	16.49	3.63	0.83
Other Operating Activities	10.61	-35.19	0.86	2.85	0.87
Operating Cash Flow	-50.93	-14.43	-32.58	-11.03	-18.68
Capital Expenditures	-5.41	-5.75	-1.15	-0.29	-0.12
Acquisitions	0	0	-11.77	0	0
Investing Cash Flow	-5.41	-5.75	-12.91	-0.29	-0.12
Share Issuance / Repurchase	2.04	0.48	225.85	0	0
Debt Issued / Paid	0	-0.16	0	41.18	0
Other Financing Activities	-0.16	-	-3.11	0.25	2.04
Financing Cash Flow	1.87	0.33	222.74	41.44	2.04
Exchange Rate Effect	2.17	0.19	-6.46	1.72	-0.44
Net Cash Flow	-52.3	-19.67	170.79	31.83	-17.21
Free Cash Flow	-56.34	-20.18	-33.73	-11.32	-18.81
Free Cash Flow Margin	-7024.69%	-45.14%	-12585.45%	-234.83%	-274.74%
Free Cash Flow Per Share	-1.47	-0.54	-1.30	-1.43	-0.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).